Every one of those 1 sits in a single category, market-trends. David Gilboa is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Seer, Inc.
Every one of those 1 sits in a single category, market-trends. David Gilboa is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window. Their average consequence score of 5 runs below the beat's 5.7 for that window. We currently track 1 Healthcare story that mention Seer, Inc., all published on February 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Seer, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Warby Parker and Seer, Inc. reported Q4 2025 results, highlighting a pivot toward integrated health platforms and advanced diagnostic capabilities. While Warby Parker expands its telehealth and physical eye care ecosystem, Seer is accelerating the commercialization of its proteomics technology to redefine precision medicine.